Matching articles for "PCV7"
Issue 1734 · August 4, 2025 Free
Comparison Table: Pneumococcal Vaccine Recommendations for Adults 19-49 Years Old (online only)

View the Comparison Table: Pneumococcal Vaccine Recommendations for Adults 19-49 Years Old

Med Lett Drugs Ther. 2025 Aug 4; 67(1734):e1 doi:10.58347/tml.2025.1734f
View the Comparison Table: Pneumococcal Vaccine Recommendations for Adults 19-49 Years Old
Issue 1734 · August 4, 2025 Free
Comparison Table: Pneumococcal Vaccine Recommendations for Adults ≥50 Years Old (online only)

View the Comparison Table: Pneumococcal Vaccine Recommendations for Adults ≥50 Years Old

Med Lett Drugs Ther. 2025 Aug 4; 67(1734):e1 doi:10.58347/tml.2025.1734g
View the Comparison Table: Pneumococcal Vaccine Recommendations for Adults ≥50 Years Old
Issue 1345 · August 23, 2010
An Expanded Pneumococcal Vaccine (Prevnar 13) for Infants and Children

The FDA has licensed a 13-valent conjugate pneumococcal vaccine (PCV13; Prevnar 13 – Pfizer) for the prevention of invasive pneumococcal disease (IPD) in infants and children <6 years old. It replaces…

Med Lett Drugs Ther. 2010 Aug 23; 52(1345):67-8
The FDA has licensed a 13-valent conjugate pneumococcal vaccine (PCV13; Prevnar 13 – Pfizer) for the prevention of invasive pneumococcal disease (IPD) in infants and children <6 years old. It replaces Prevnar (PCV7). An unconjugated 23-valent polysaccharide vaccine (PPSV23; Pneumovax 23 – Merck) is FDA-approved for use in adults.
Issue 1314 · June 15, 2009 Free
Pneumococcal Vaccination of Adults: Polysaccharide or Conjugate?

A 23-valent polysaccharide vaccine (PPSV23; Pneumovax 23 - Merck) is the only pneumococcal vaccine approved for use in adults. It has reduced the risk of invasive pneumococcal disease (meningitis or bacteremic…

Med Lett Drugs Ther. 2009 Jun 15; 51(1314):47-8
A 23-valent polysaccharide vaccine (PPSV23; Pneumovax 23 - Merck) is the only pneumococcal vaccine approved for use in adults. It has reduced the risk of invasive pneumococcal disease (meningitis or bacteremic pneumonia), but not mortality, in immunocompetent older adults.2 PPSV23 has not been shown to reduce the risk of invasive pneumococcal disease (IPD) in immunocompromised patients. Click here to view the free full article.
Issue 80 · April 1, 2009
Adult Immunization

Although immunization programs have produced high vaccination rates in US infants and children, similar successes have not been achieved in adults. Vaccines recommended for routine use in adults are reviewed…

Treat Guidel Med Lett. 2009 Apr; 7(80):27-36
Although immunization programs have produced high vaccination rates in US infants and children, similar successes have not been achieved in adults. Vaccines recommended for routine use in adults are reviewed here. Vaccines for travel are reviewed separately.